Incorporation of host complement regulatory proteins into Newcastle disease virus enhances complement evasion.
about
Oncolytic viruses as therapeutic cancer vaccinesAvian Paramyxovirus: A Brief ReviewA novel factor I activity in Nipah virus inhibits human complement pathways through cleavage of C3bComprehensive Analysis and Characterization of Linear Antigenic Domains on HN Protein from Genotype VII Newcastle Disease Virus Using Yeast Surface Display System.Newcastle Disease Virus: Potential Therapeutic Application for Human and Canine Lymphoma.Genetic Modification of Oncolytic Newcastle Disease Virus for Cancer Therapy.Paramyxovirus activation and inhibition of innate immune responses.Oncolytic viruses and their application to cancer immunotherapyMultimodal cancer therapy involving oncolytic newcastle disease virus, autologous immune cells, and bi-specific antibodies.Parainfluenza virus 5 upregulates CD55 expression to produce virions with enhanced resistance to complement-mediated neutralization.Intravenously injected Newcastle disease virus in non-human primates is safe to use for oncolytic virotherapy.Point mutations in the paramyxovirus F protein that enhance fusion activity shift the mechanism of complement-mediated virus neutralization.Prostate-specific antigen-retargeted recombinant newcastle disease virus for prostate cancer virotherapy.Stability, biophysical properties and effect of ultracentrifugation and diafiltration on measles virus and mumps virus.Genetically engineered Newcastle disease virus for prostate cancer: a magic bullet or a misfit.CD59 association with infectious bronchitis virus particles protects against antibody-dependent complement-mediated lysis.Hepatitis B virus inhibits the expression of complement C3 and C4, in vitro and in vivo.
P2860
Q21245758-D829C228-78C1-4E7F-8683-ABD03A2BB650Q28261383-2CA4AC16-1C2A-40BF-95A7-8528F5D35BA6Q34991123-D5921942-A955-493C-ADCB-87DBFCD619F9Q35677122-4B52FB93-5F06-457E-BEB5-0E40ED5F86BEQ36507259-54078521-6FC5-4713-BEAF-FA4088139919Q37069810-818A058A-8FFD-4EE0-8E00-4FBBF164D96AQ37613401-261FAD52-00B7-468B-B5BF-4DE3CEF142D5Q38207011-22F27202-BBC3-4A9D-B1C1-C1D3B2875F98Q38259582-7805F534-498B-44D3-913D-BE6D884A6034Q38752894-4519B527-FEA5-42DC-841B-F5E0976016F3Q38953230-A5E2591C-AF77-42CE-9D53-52F296029DB0Q39137369-542803DA-54BA-43A8-9523-94E591747D25Q39789912-E499F92C-FB35-4E17-A48D-08D940190318Q39952994-3E8DB513-EDB4-4638-A877-2DBA36E23A1AQ44319257-ACF6C2DE-5EFC-4867-A17E-561FAA2AB544Q45325724-45B04A3B-158A-442B-A508-C020AFA9645FQ54957289-311EBDF9-1268-4301-AFEE-ECF749892FC7
P2860
Incorporation of host complement regulatory proteins into Newcastle disease virus enhances complement evasion.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Incorporation of host compleme ...... s enhances complement evasion.
@en
type
label
Incorporation of host compleme ...... s enhances complement evasion.
@en
prefLabel
Incorporation of host compleme ...... s enhances complement evasion.
@en
P2093
P2860
P356
P1433
P1476
Incorporation of host compleme ...... us enhances complement evasion
@en
P2093
Griffith D Parks
John B Johnson
Sandeep R P Kumar
Subbiah Elankumarana
P2860
P304
12708-12716
P356
10.1128/JVI.00886-12
P407
P577
2012-09-12T00:00:00Z